To update the clinical outcome of an elderly women cohort with early breast cancer who underwent accelerated partial breast irradiation (APBI) based on a post-operative single fraction of multicatheter interstitial high dose–rate brachytherapy (MIB).
Material and methods
A single institution retrospective cohort study was performed focusing on elderly patients (≥ 65 years old) presenting a low-risk breast carcinoma treated by lumpectomy plus axillary evaluation followed by MIB APBI. A single fraction of 16 Gy was prescribed on the 100% isodose. Clinical outcome at 5 years was reported based on local relapse free survival (LRFS), specific survival (SS) and overall survival (OS). Late toxicity was evaluated. Cosmetic results were evaluated clinically by the physician.
Results
Between January 2012 and August 2015, 48 women (51 lesions) were treated. Median age was 77.7 years (range: 65–92) with a median tumor size of 12 mm (range: 3–32). Five patients (pts) presented an axillary lymph node involvement (4 Nmic, 1 N1). Invasive ductal carcinoma was the most frequent histology type (86.3%). With a median follow–up of 64 months (range: 56–71), no local relapse occurred while 1 pt. developed an axillary relapse (2.1%). No Grade 3 or higher late toxicity was observed while 16 late toxicities occurred (G1: 14 events [87.5%) mainly G1 breast fibrosis). The rate of excellent cosmetic outcome was 76.4%.
Conclusion
We confirmed the safety of the process and remained encouraging clinical outcome of a post-operative single fraction of MIB ABPI in the elderly. This approach leads to consider a very APBI as an attractive alternative to intra-operative radiation therapy while all the patients will be good candidates for APBI in regards to the post-operative pathological report.
Hinweise
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
APBI
Accelerated partial breast irradiation
ASTRO
American Society of Radiation Oncology
DNR
Dose non-homogeneity ratio
GEC-ESTRO
Groupe Européen de Curiethérapie of the European Society for Radiotherapy and Oncology
HDR
High-dose rate
IORT
Intraoperative radiation therapy
LRFS
Local relapse-free survival
MIB
Multicatheter interstitial brachytherapy
OS
Overall survival
PS
Performans Status
RRFS
Regional relapse-free survival
SS
Specific survival
vAPBI
very APBI
WBI
Whole breast irradiation
Background
After more than two decades of clinical research, accelerated partial breast irradiation (APBI) is considered as an efficient and safe adjuvant treatment for low-risk breast cancer [1, 2]. American Society of Radiation Oncology (ASTRO) and Groupe Européen de Curiethérapie of the European Society for Radiotherapy and Oncology (GEC-ESTRO) now consider that, in a well selected population, described as “suitable” (ASTRO) and “low-risk” (ESTRO), adjuvant APBI can be proposed as an alternative to standard or slightly hypofractionnated adjuvant schedule (4 to 6 treatment weeks) [3, 4].
A single fraction of adjuvant APBI using multicatheter interstitial brachytherapy (MIB) permits the maximal reduction of transportations and alleviates the treatment related constraints mainly for elderly patients with frequent comorbidities [5]. The single fraction schedule was challenged in retrospective and prospective studies and remained encouraging outcomes [6‐9]. We already reported the early clinical outcome of a cohort of elderly women treated by a post-operative single fraction of very APBI (vAPBI) but a longer follow-up was needed to assess consistent results [9].
Anzeige
The aim of this short report was to update the clinical outcome after vAPBI in our previously published cohort of elderly patients presenting low-risk breast cancer.
Material and methods
All material and methods sections were previously described in details [9].
Patient selection
This is a single institution retrospective study including elderly patients presenting with low-risk breast cancer who underwent lumpectomy plus axillary evaluation followed by a single fraction of high-dose rate (HDR) MIB APBI. The patient cohort combined women enrolled in a prospective phase I/II trial (SiFEBI; Clinical.gov #NCT01727011, [7]) and elderly frail patients treated before the SiFEBI trial opening. Briefly, inclusion criteria were as follow: elderly women 65 years and older, histologically proven breast carcinoma with free surgical margins, negative axillary evaluation. Patients were excluded in case of: sarcoma or lymphoma histology or with metastatic dissemination.
Treatments
Breast surgery
Patients underwent lumpectomy with axillary management (sentinel lymph node or axillary dissection). Four to five clips were clamped by the surgeon to mark the tumor bed before closing the lumpectomy cavity [10].
Brachytherapy
Brachytherapy was performed according to the GEC-ESTRO Breast Cancer Working Group recommendations for MIB APBI [11]. A post-implant CT scan was performed in order to delineate the clinical target volume (CTV) based on clips, surgical cavity and pathological margins including a total safety margin of about 2 cm [12]. A single fraction of 16 Gy was prescribed to the 100% isodose. Dose constraints were as follow: D90% ≥ 105% of the prescribed dose, D100% ≥ 75%, V100 > 95% of the CTV, V150 ≤ 40%, V200 ≤ 15%; dose non-homogeneity ratio (DNR) ≤ 35% [7].
Systemic therapy
Systemic therapies such as adjuvant chemotherapy and/or hormonal treatments were dispensed according to the protocols used in the Antoine Lacassagne Cancer Center.
Follow up
The radiation oncologist performed iterative monthly post-brachytherapy clinics during 3 months (acute brachytherapy side effects). Then, clinical surveillance was performed twice a year, alternatively with the surgeon, with a yearly mammogram. Late toxicities were evaluated by Common Terminology Criteria for Adverse Event v4 (CTCAE.V4.0). Cosmetic evaluation was performed according to Harvard criteria [13].
Anzeige
Statistical analysis
Description of the study population and of the different investigated parameters was made using absolute and relative frequencies for the qualitative data and summarized using descriptive statistics such as median, extreme for quantitative data. Survival time was defined between the surgery date and the event date. Local relapse free-survival (LRFS), regional relapse free-survival (RRFS), specific (SS) and overall survivals (OS) were estimated using the Kaplan-Meier method. Patients still alive were censored at the date of last follow-up. Median follow-up with 95% confidence intervals was calculated by reverse Kaplan–Meier method. Data entry and data management were performed on Ennov clinical® system and were analyzed using R 3.2.2 for Windows®.
Results
Patient and tumor characteristics
Between January 2012 and August 2015, a total of 51 lesions from 48 patients (pts) were treated with a vAPBI. Patient, tumor and treatment features are reported in Table 1. Patient median age was 77.7 years [range: 65–92]. Most of patients were Performans Status (PS) 0 (85%). The most frequent location was the upper external quadrant (39.2%). Histological type was mainly invasive ductal carcinoma (86.2%). The median tumor size was 12 mm [range: 3–32] while, 4 pts. presented with a microscopic node involvement (Nmic) and 1 pt. was classified N1. The median surgical margin was 5 mm [range: 1–10]. One lesion was associated with peri-neural invasion. All the tumors but three had positive hormonal receptor status while Her-2 status was over-expressed in 5 pts (9.8%).
Table 1
Patient, lesion and treatment characteristics
Patient features
Number of patients
%/(min – max)
Median age (years)
77.7
65.2–92.3
Performans Status
0
41
85.5
1
7
14.5
Tumor side
Left
28
54.9
Right
23
45.1
Median tumor size (mm)
12
3–32
Tumor stage
T1a
28
54.9
T1b
18
35.3
T1c
5
9.8
Axillary lymph node status
N0
46
90.1
N1mic
4
7.9
N1
1
2.0
Histology type
Invasive ductal carcinoma
44
86.3
Invasive lobular carcinoma
3
5.9
Other
4
7.8
Histological grade
1
32
62.7
2
14
27.4
3
5
9.8
Hormonal status
Positive
48
94.1
Negative
3
5.9
Her-2 status
Over-expressed
5
9.8
Non-over-expressed
46
90.2
Peri-neural invasion
Yes
1
1.9
No
50
98.1
Median Ki-67 (%)
Median surg. Marg.(mm)
10
5
5–60
1–10
Implant procedure
Intra operative
47
92.2
Post-operative
4
7.8
Median time interv. Surg./APBI (d)
7
1–63
Median number of lines
11
5–15
Median number of planes
2
1–3
Median CTV (cc)
44
11–124
Median V100% (%)
96
86–100
Median V150% (%)
34
23–48
Median V200% (%)
12
8–21
MedianDNR
0.35
0.23–0.56
Median time interv. Surg./APBI Median time between intervention and APBI Median surg. marg. median surgical margins, DNR Dose non-homogeneity ratio: V100/V150
Treatment characteristics
The median time interval between surgery and vAPBI was 7 days [range: 1–63]. A median number of 11 vectors [range: 5–15] on 2 planes [range: 1–3] were implanted, mainly intra-operatively (92.2%). The median CTV was 44 cc [range: 11–124]. The median V100% was 96% [range: 86–100] (Table 1).
Oncological outcome
With a median follow–up of 64 months [range: 56–71], no local relapse occurred while 1 pt. developed an axillary relapse (2.1%). Five-year LRFS, and SS were 100% and 5-year OS was 87.3% [78.3–97.3] (Fig. 1).
Fig. 1
Overall and specific survival
×
Toxicity
Acute toxicity was previously reported [9]. No G ≥ 3 late toxicity was observed. Sixteen late toxicities occurred (G1: 14 events [87.5%]). G1 breast fibrosis and hypopigmentation of puncture site were the most frequent late side effects. The rates of excellent and good cosmetic outcome were 76.4 and 25.6% respectively. A breast asymmetry was noticed in 2 pts (4%) (Table 2).
Table 2
Late toxicity outcome
Late Toxicity
Number of events
%
Grade 1
Breast fibrosis
5
31.3
Puncture site hypopig.
5
31.3
Telangectasia
2
12.5
Epithelitis
1
6.3
Other
1
6.3
Total
14
87.5
Grade 2
Breast fibrosis
2
12.5
Total number of events
16
100
Cosmetic outcome
Number of estimations
%
Excellent
39
76.4
Good
12
25.6
Puncture site hypopig Puncture site hypopigmentation
Discussion
This update short report confirms the excellent outcome of our cohort [9]. After a median follow-up of 64 months, no local relapse occurred while SS rate was 100% in this elderly cohort. The challenge in this population is alleviating the treatment, preserving oncological outcome and functional status. A vAPBI based on a post-operative single fraction appeared as an attractive technical option. Indeed, it drastically reduces the number of transportations, alleviates the treatment related constraints (mainly for elderly patients with frequent comorbidities) without compromise regarding local control [5]. Furthermore, the post-operative irradiation setting permits treating only validated candidates for APBI due to an appropriate definitive pathological report compatible with APBI criteria.
vAPBI also could be considered as a smart alternative to the omission of adjuvant radiation therapy which has been considered for elderly patients. Indeed, in phase III randomized trials which compared surgery + hormonal therapy with or without adjuvant WBI, there was a significant over-risk of local recurrence without breast irradiation [14, 15]. In our study, there was no local relapse and there was no cancer related death. Due to the deleterious impact of aromatase inhibitors on the quality of life [16], it is currently discussed to promote adjuvant breast irradiation without hormonal therapy in the elderly with low-risk breast cancer [17, 18].
Other studies reported encouraging results of vAPBI in patients presenting low-risk breast cancer and confirmed the safety and the efficiency of this new approach (Table 3) [6‐8, 19‐23].
Table 3
Very APBI discribed in the litterature
Authors
Year
# pts
MFU (months)
Irradiation techniques
Total dose (Gy)
D/f (Gy)
AG3 tox (%)
LG3 tox (%)
LF (%)
RF (%)
DM (%)
Ex/goodcosmetic results
Sacchini
2008
1834
31
HDRIORT
20/18
20/18
7.7
–
0
–
–
a
Khan
2013
30
11
Contura™
28
7 (BID)
0
0
–
–
–
–
Wilkinson
2012/17
45
74
Mammosite™
28
7 (BID)
13.3
2
0
0
0
91
Showalter
2016
28
6
HDRIORT
12.5
12.5
0
–
–
–
–
93
Latorre
2018
20
24
HDRMIB
18
18
0
0
0
0
5
80
Khan
2019
200
12
HDRMIB/Contura™
22,5
7,5
1.5
–
1
–
–
97
Jethwa
2019
73
14
Balloon
21
7
3
–
–
–
–
–
SiFEBI
2018/19
26
63
HDRMIB
16
16
7.6
0
0
0
–
88
Study
–
48
39
HDRMIB
16
16
6.3
0
0
2
0
100
# pts. number of patients, MFU Median follow-up, HDRIORT High-dose rate brachytherapy performed intra-operatively, MIB Multicatheter interstitial high-dose rate brachytherapy, Dose/f Dose per fraction, AG3tox Acute Grade 3 toxicity, LG3tox Late Grade 3 toxicity, LF Local failure, RF Regional failure, DM Distant metastasis, Ex/gd cosmetic results Percentages of excellent and good cosmetic results, APBI Accelerated partial breast irradiation
aCosmetic results were better with 18 Gy compared to 20 Gy
Anzeige
Conclusion
We confirmed promising and encouraging clinical outcome of a post-operative single fraction of MIB ABPI in the elderly. This approach leads to consider vAPBI as an attractive alternative to intra-operative radiation therapy while all the patients will be good candidates for APBI in regards to the post-operative pathological report. VAPBI allows to drastically reducing the number of transportations and fatigue for elderly patients.
Acknowledgements
N006F
Ethics approval and consent to participate
This study was approved by the local ethic committee of the Antoine Lacassagne Cancer Center.
A statement on ethics approval and consent was provided by the Breast Cancer Research Board of the Antoine Lacassagne Cancer Center.
Anzeige
Consent for publication
Consent for publication was obtained from the patients.
Competing interests
The authors declare that they have no competing interests
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
